Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Learn about the burden of influenza, guideline updates for treatment, timing of antiviral initiation and more.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity on June 11, 2020 AND received
CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-20-278-L01-P),
you are NOT allowed to also receive credit for the home-study on-demand web portion
of this activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
As the world shifts focus to mortality reduction during the COVID-19 pandemic,
clinicians may find themselves strained when managing serious bacterial infections.
Gram-negative infections often appear in the most critically ill patients, and with
a potential for considerable strain on ICU beds, continuing education may significantly
impact outcomes. As novel antibiotics are approved, appropriate and conservative use
may be essential to maintain their efficacy.
Clinical and infectious diseases professionals must have the most up to date information about the spectrum of antimicrobial activity, dosing, adverse effects, and place in therapy to guide appropriate use of new agents and information about emerging therapies on the horizon. Importantly, an analysis of which agent is approved for what indication, the gram-negative coverage profile, unique patient considerations – such as renal or hepatic impairment – and overall dosing and monitoring are critical in managing new treatments.
In part 1 of this activity, subject matter experts will discuss the knowledge and practice surrounding the use of antibiotics for gram-negative infections in an on-demand webinar. Part 2 of this activity is a podcast featuring Drs. Keith Kaye and Kim Claeys as they answer the questions viewers submitted. Listeners will benefit from this worthwhile content which focuses on empiric therapy selection, formulary, microbiology lab susceptibility testing, rapid diagnostics and dosing.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Kimberly C. Claeys, PharmD, BCPS
Assistant Professor Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Keith S. Kaye, MD, MPH
Professor of Internal Medicine
Director of Research, Division of Infectious Diseases
University of Michigan Medical School
Ann Arbor, Michigan
Release Date: June 11, 2020
Expiration Date: July 31, 2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-20-278-H01-P and 0221-9999-20-299-H01-P have been assigned to this two-part home study, knowledge-based activity (initial release date 6-11-2020). This activity is approved for 2.25 contact hours (0.225 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Claeys is a speaker for GenMark Diagnostics, and has provided study supplies for BioFire Diagnostics and GenMark Diagnostics. Dr. Kaye is a consultant for Melinta, Merck, and Shionogi, and is a stock shareholder of Merck. Potential conflict of interest was resolved with an outside peer review.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.